Related Experiment Video
Updated: Jan 8, 2026
Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
Published on: January 20, 2015
Can aging be 'drugged'?
Celine E Riera1,2,3, Andrew Dillin1,2,3
1Department of Molecular and Cell Biology, University of California, Berkeley, California, USA.
Abstract:
The engines that drive the complex process of aging are being identified by model-organism research, thereby providing potential targets and rationale for drug studies. Several studies of small molecules have already been completed in animal models with the hope of finding an elixir for aging, with a few compounds showing early promise. What lessons can we learn from drugs currently being tested, and which pitfalls can we avoid in our search for a therapeutic for aging? Finally, we must also ask whether an elixir for aging would be applicable to everyone, or whether we age differently, thus potentially shortening lifespan in some individuals.
Insights
Researchers are identifying aging mechanisms using model organisms to develop anti-aging drugs. Current drug studies in animals show promise, but we must learn from past pitfalls and consider individual aging differences.
Area of Science:
- Gerontology and drug discovery
- Model organism research in aging
Background:
- Aging is a complex process driven by identifiable biological mechanisms.
- Model organism research is crucial for understanding aging and identifying therapeutic targets.
- Early-stage drug studies in animal models are exploring potential anti-aging interventions.
Purpose of the Study:
- To review lessons learned from current drug studies targeting aging.
- To identify potential pitfalls in the development of aging therapeutics.
- To discuss the applicability of anti-aging interventions across diverse individuals.
Main Methods:
- Review of existing literature on small molecule studies in animal models of aging.
- Analysis of current drug testing strategies for aging.
- Consideration of individual variability in aging processes.
Main Results:
- Model organisms have revealed key drivers of aging, offering drug targets.
- Some small molecules show promise in preclinical aging studies.
- The search for an "elixir of aging" requires careful consideration of methodology and individual differences.
Conclusions:
- Understanding aging mechanisms in model organisms provides a foundation for therapeutic development.
- Lessons from ongoing drug studies can help avoid common pitfalls.
- The heterogeneity of aging necessitates personalized approaches to anti-aging therapies.
Related Concept Videos
09:21Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
10:54Reliable Identification of Living Dopaminergic Neurons in Midbrain Cultures Using RNA Sequencing and TH-promoter-driven eGFP Expression
08:45Isolation, Culture and Long-Term Maintenance of Primary Mesencephalic Dopaminergic Neurons From Embryonic Rodent Brains
09:35Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
11:58Primary Culture of Mouse Dopaminergic Neurons
09:54Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area